GERALD I SHULMAN, MD
Osteopathic Medicine in New Haven, CT
License number
Connecticut 027683
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
789 Howard Ave Dana Building FLOOR 3RD, New Haven, CT 06519
Phone
(203) 737-1932
(203) 785-3588 (Fax)
(203) 785-3588 (Fax)
Personal information
See more information about GERALD I SHULMAN at radaris.comName
Address
Phone
2 Old Town Hwy UNIT 15, East Haven, CT 06512
2 Old Town Hwy UNIT 19, East Haven, CT 06512
12 Old Town Hwy, East Haven, CT 06512
2 Old Town Hwy, East Haven, CT 06512
Organization information
See more information about GERALD I SHULMAN at bizstanding.comGerald I Shulman MD
300 Cedar St #S269, New Haven, CT 06519
Categories:
Pulmonary & Respiratory Physicians & Surgeons
Phone:
(203) 785-5447 (Phone)
Professional information
Dr. Gerald I Shulman, New Haven CT - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Yale School Of Medicine
300 Cedar St SUITE S269, New Haven 06519
(203) 785-5447 (Phone)
300 Cedar St SUITE S269, New Haven 06519
(203) 785-5447 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1985, Internal Medicine, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Yale School Of Medicine
300 Cedar St SUITE S269, New Haven 06519
Yale - New Haven Hospital
20 York St, New Haven 06510
300 Cedar St SUITE S269, New Haven 06519
Yale - New Haven Hospital
20 York St, New Haven 06510
Education:
Medical School
Wayne State University
Graduated: 1979
Duke University Hospital
Mass Genl Hosp/Harvard
Wayne State University
Graduated: 1979
Duke University Hospital
Mass Genl Hosp/Harvard
Modulation Of Phosphoenolpyruvate Carboxykinase-Mitchondrial (Pepck-M) Expression
US Patent:
2013021, Aug 22, 2013
Filed:
Jun 10, 2011
Appl. No.:
13/702965
Inventors:
Sanjay Bhanot - Carlsbad CA, US
Gerald Shulman - East Haven CT, US
Gerald Shulman - East Haven CT, US
Assignee:
Yale University - New Haven CT
Isis Pharmaceuticals, Inc. - Carlsbad CA
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K 31/7088
US Classification:
514 44 A
Abstract:
Provided herein are methods, compounds, and compositions for reducing expression of phosphoenolpyruvate carboxykinase-mitochondrial (PEPCK-M) mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preventing or decreasing diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia, or a symptom thereof.
Methods For Modulating Expression Of Creb
US Patent:
2011017, Jul 21, 2011
Filed:
May 22, 2009
Appl. No.:
12/993435
Inventors:
Gerald Shulman - East Haven CT, US
Sanjay Bhanot - Carlsbad CA, US
Brett P. Monia - Encinitas CA, US
Sanjay Bhanot - Carlsbad CA, US
Brett P. Monia - Encinitas CA, US
International Classification:
A61K 39/395, A61K 31/7088, A61K 38/02, A61K 31/7125, A61K 31/712, A61K 31/7115, A61P 3/00, A61P 9/00, A61P 3/06, A61P 3/04, A61P 3/10, A61P 9/10, A61P 1/16, A61P 5/50
US Classification:
4241721, 514 44 R, 514 74, 514 68, 514 11, 514 48
Abstract:
Methods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of CREB. The present invention is also directed to methods of decreasing lipid levels in a subject or for preventing or delaying the onset of a rise in lipid levels in a subject, comprising administering to said subject a CREB-specific inhibitor.
Transgenic Fatty Acid Transport One (Fatp1) Non-Human Knockout Mammals Uses Thereof
US Patent:
2003016, Sep 4, 2003
Filed:
Dec 12, 2002
Appl. No.:
10/319384
Inventors:
Gerald Shulman - East Haven CT, US
Jason Kim - Hamden CT, US
Ruth Gimeno - Wellesley MA, US
Harvey Lodish - Brookline MA, US
David Hirsch - Somerset NJ, US
Andreas Stahl - Mountain View CA, US
Jason Kim - Hamden CT, US
Ruth Gimeno - Wellesley MA, US
Harvey Lodish - Brookline MA, US
David Hirsch - Somerset NJ, US
Andreas Stahl - Mountain View CA, US
Assignee:
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:
A61K049/00
US Classification:
424/009200, 800/003000
Abstract:
The present invention provides a transgenic Fatty Acid Transport One (FATP1), non-human knockout mammal, e.g., mammal, useful for elucidating the function of FATP in intact animals whose genomes comprise a wild-type FATP gene. Further aspects of the invention provide a method for the identification of agents, e.g., therapeutic agents, that inhibit FATP1 activity, and methods of treating diseases or conditions associated with FATP1 function, e.g., insulin resistance, non-insulin dependent diabetes mellitus, and cellular triglyceride accumulation.